Target of 360 for Venus Remedies: Seshadri Bharathan

ET Now spoke to Seshadri Bharathan, MD & CEO, KSEMA Fincon Ltd, on his views on the market.

ET Now: You have a very aggressive target on Venus Remedies.

Seshadri Bharathan: Definitely yes. This company is more into pharma products business. Company has got 19 patents and some of the regulated countries in the world can be the potential growth markets for this company.

We have seen that the earnings per share going forward for FY11 would be around Rs 60. The stock trades roughly around 4.5 times the earnings per share for FY11. So my sense is that investors can buy into the stock and expect the price to appreciate to around Rs 360 levels.